On a geographic basis, United States revenue was $117.4 million, an increase of 11% from 2011. International revenue was $22.8 million, an increase of 7% (13% on a constant currency basis) from 2011.

Net income for the twelve months ended December 31, 2012 was $2.2 million, or $0.06 per diluted share, compared with net income of $894,000 or $0.03 per diluted share, in the twelve months ended December 31, 2011. Non-GAAP adjusted net income for the twelve months ended December 31, 2012 was $2.5 million, or $0.07 per diluted share, and for the twelve months ended December 31, 2011 was $2.7 million, or $0.08 per diluted share. Non-GAAP adjusted net income excludes special items described later in this release under the heading "Reconciliation of Non-GAAP Financial Measures."

2013 Outlook

Management projects that 2013 revenue will be in the range of $153.0 - $155.5 million, an increase of 9% - 11% from 2012.

Net income for 2013 is projected to be in the range of $0.0 - $0.5 million, or $0.00 - $0.01 per diluted share, including the impact of the Medical Device Tax which is estimated to be approximately $2.5 million for 2013. Projected net income also includes estimated non-cash amortization costs of approximately $1.6 - $2.0 million associated with the recently announced acquisition of the Quick-Access™ and Quick-Cross Capture™ devices.

Earnings before interest, taxes, depreciation, amortization, special items and the medical device tax (Adjusted EBITDA) is anticipated to be in the range of $13.5 - $14.5 million in 2013, compared with Adjusted EBITDA of $13.1 million in 2012. Adjusted EBITDA provides for comparability between periods and represents an additional measure of the operating performance of the business.

As a result of seasonal operating expenses that are higher in the first half of the year, investments in research, development and commercial programs, non-cash amortization costs associated with the previously announced acquisition, and the impact of the medical device tax, a net loss of up to $2.5 million is anticipated in the first half of 2013, mostly in the first quarter.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

5 Things You Must Know Before the Market Opens Wednesday

Philips Buys Medical Device Maker Spectranetics Corp.; Deal Has Enterprise Value of $2.15 Billion

Strong On High Relative Volume: Spectranetics (SPNC)

Today's Perilous Reversal Stock: Spectranetics (SPNC)